Avanos Medical (AVNS)
(Delayed Data from NYSE)
$23.02 USD
+0.53 (2.36%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $23.03 +0.01 (0.04%) 5:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.02 USD
+0.53 (2.36%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $23.03 +0.01 (0.04%) 5:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
Zacks News
Brookdale (BKD) Q1 Adjusted EBITDA to Beat View, Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 17 straight months of year-over-year increases in weighted average occupancy level.
Illumina (ILMN) Partners With Henry Ford Health for NGS Test
by Zacks Equity Research
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.
Thermo Fisher (TMO) Expands to Boost Commercial Manufacturing
by Zacks Equity Research
Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions.
Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental
by Zacks Equity Research
Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.
CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually
by Zacks Equity Research
CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Quest Diagnostics (DGX) Advances Access to Transplant Services
by Zacks Equity Research
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
by Zacks Equity Research
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
National Vision (EYE) Rides on Comps Growth Amid Macro Issues
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Illumina (ILMN) to Expand Genomics Capacity With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
by Zacks Equity Research
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.
3 Reasons to Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
by Zacks Equity Research
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Community Health (CYH) Divests Hospital for $92 Million
by Zacks Equity Research
Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.
LabCorp (LH) Expands Colon Cancer Test Access With New Pact
by Zacks Equity Research
LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.